🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 13 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/11/2023 15,79 16,52 15,58 16,45 +5,65% 5,95% 1.488.100
06/11/2023 16,53 16,53 15,35 15,57 -4,89% 7,14% 2.067.400
03/11/2023 16,09 16,76 16,09 16,37 +3,94% 4,16% 1.082.800
02/11/2023 16,22 16,48 15,60 15,75 -0,44% 5,43% 834.900
01/11/2023 15,84 15,85 15,46 15,82 +0,70% 2,46% 666.600
31/10/2023 14,85 15,74 14,73 15,71 +5,08% 6,84% 732.600
30/10/2023 14,49 15,10 14,47 14,95 +4,33% 4,35% 730.500
27/10/2023 16,01 16,01 14,33 14,33 -9,99% 10,49% 881.400
26/10/2023 15,66 16,14 15,56 15,92 +1,66% 3,67% 487.800
25/10/2023 15,69 16,06 15,53 15,66 -1,32% 3,38% 489.500
24/10/2023 16,33 16,66 15,54 15,87 -1,92% 6,89% 868.500
23/10/2023 16,04 16,38 15,84 16,18 +0,37% 3,37% 794.500
20/10/2023 15,69 16,37 15,52 16,12 +2,28% 5,42% 750.800
19/10/2023 16,14 16,28 15,68 15,76 -2,48% 3,69% 667.400
18/10/2023 16,42 16,46 16,06 16,16 -2,00% 2,41% 695.700
17/10/2023 16,24 16,90 16,24 16,49 +0,86% 4,06% 560.500
16/10/2023 16,12 16,80 16,12 16,35 +1,43% 4,22% 603.900
13/10/2023 15,91 16,35 15,65 16,12 +1,90% 4,40% 575.400
12/10/2023 16,39 16,39 15,53 15,82 -3,24% 5,25% 571.500
11/10/2023 16,62 16,79 16,17 16,35 -1,74% 3,73% 354.500
10/10/2023 16,36 16,91 16,30 16,64 +1,40% 3,73% 430.800
09/10/2023 16,56 16,57 16,00 16,41 -1,80% 3,44% 476.600
06/10/2023 16,10 16,71 16,07 16,71 +2,01% 3,98% 660.300
05/10/2023 15,69 16,68 15,64 16,38 +3,54% 6,63% 1.373.200
04/10/2023 17,00 17,03 15,75 15,82 -7,27% 7,53% 852.700
03/10/2023 17,24 17,73 17,00 17,06 -1,33% 4,23% 900.900
02/10/2023 17,87 17,93 17,01 17,29 -3,68% 5,15% 1.004.700
29/09/2023 18,30 18,48 17,62 17,95 -0,61% 4,70% 877.700
28/09/2023 18,60 18,60 17,75 18,06 -3,68% 4,57% 1.516.100
27/09/2023 19,01 19,35 18,51 18,75 -2,34% 4,42% 571.500